secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001297184-26-000007
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74
--------------------------------------------------------------------

- Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.
- GAAP net income Q4 $24.4M ($0.51 diluted EPS) vs $38.0M ($0.74) in Q4 2024; FY $98.1M ($2.03) vs $159.5M ($3.06).
- Adjusted non-GAAP net income Q4 $34.2M ($0.73 diluted EPS) vs $47.2M ($0.92) a year ago.
- CEO cites BAQSIMI double-digit growth and FDA approvals of iron sucrose and teriparatide injections as positives.
- Three novel peptides and a synthetic corticotropin compound added to pipeline for oncology, ophthalmology, and immunology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/0001297184-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/amph-20260226x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer